Indianapolis, Indiana, U.S., September 24, 2026
Eli Lilly and Company has received U.S. Food and Drug Administration (FDA) approval for Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection designed to improve blood glucose control in adults living with type 2 diabetes. Announced on September 24, 2026, in Indianapolis, Indiana, the approval introduces a weekly basal insulin option into Lilly’s diabetes portfolio. Onswik is indicated as an adjunct to diet and exercise for adults with type 2 diabetes and is designed to provide steady basal insulin levels over seven days. According to Lilly, the treatment could reduce the number of basal insulin injections by more than 300 per year compared with once-daily basal insulin, potentially reducing the frequency of injections associated with long-term diabetes management.
FDA Approval Supported by QWINT Phase 3 Program
The FDA decision was supported by the QWINT Phase 3 clinical development program, which enrolled more than 3,400 adults with type 2 diabetes across four registration studies. The trials evaluated once-weekly insulin efsitora against established daily basal insulins, including insulin glargine U-100 and insulin degludec U-100. Across the QWINT studies, Onswik met the primary endpoint of non-inferior A1C reduction, demonstrating blood glucose-lowering efficacy comparable to the daily basal insulin comparators studied. The program included participants who were new to insulin therapy as well as adults already receiving basal insulin, providing data across different treatment settings. QWINT-1 compared weekly efsitora with insulin glargine in insulin-naïve adults, while QWINT-2 compared it with insulin degludec. QWINT-3 and QWINT-4 evaluated the treatment in people already receiving basal insulin, including participants also using mealtime insulin.
Once-Weekly Insulin Expands Diabetes Treatment Options
Onswik represents a new dosing approach within basal insulin therapy, with administration once every seven days rather than once each day. Lilly states that the treatment is designed to maintain basal insulin coverage throughout the week. The company plans to make the Onswik KwikPen available in the United States in the coming months in two concentrations, 500 units/mL and 1,000 units/mL. The approval also expands Lilly’s type 2 diabetes portfolio, which includes insulin products as well as incretin-based, oral and injectable therapies. Onswik has now received regulatory approvals in the United States, European Union, Mexico and Japan, according to Lilly.
Advertisement
Safety Profile and Clinical Considerations
In the QWINT clinical trials, Lilly reported that Onswik had an overall safety profile similar to the daily basal insulins evaluated in the studies. Reported common side effects include hypoglycemia, injection-site reactions, allergic reactions, lipodystrophy, itching, rash, swelling of the hands and feet, and weight gain. The product is not indicated for people with type 1 diabetes because of the increased risk of severe hypoglycemia. Lilly also highlights the importance of correct dosing because Onswik is supplied at high concentrations and its dosing differs from other injectable diabetes medicines. Healthcare professionals and patients will need to follow the prescribing information and product-specific instructions when using the weekly insulin pen.
The FDA approval of Onswik marks an important development in the evolution of diabetes pharmacotherapy, particularly for adults who require basal insulin and may benefit from a less frequent dosing schedule. By moving basal insulin administration from daily to weekly dosing while demonstrating non-inferior A1C reduction against established basal insulins in Phase 3 studies, Onswik adds another therapeutic option for managing type 2 diabetes. Lilly’s approval announcement positions the medicine as part of its broader effort to expand treatment choices for people managing chronic metabolic disease.
Source: Eli Lilly press release
